Reliability, availability and serviceability (RAS) is not a new concept, but AI is forcing a fundamental rethink of it.
Morning Overview on MSN
Daraxonrasib, a daily RAS-blocking pill, raised pancreatic cancer survival from 6.7 to 13.2 months with fewer severe side effects than chemo
Patients with metastatic pancreatic cancer who had already failed at least one round of chemotherapy lived roughly twice as ...
In a 500-patient phase 3 trial, daraxonrasib extends median overall survival to 13.2 vs 6.7 months for chemotherapy in second-line metastatic pancreatic cancer.
At the year’s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made ...
RAS genes constitute the most regularly mutated oncogene family in cancer. Indeed, RAS genes constituted the most regularly mutated oncogenes in the top three causes of cancer deaths in the US in 2016 ...
The targeted RAS inhibitor daraxonrasib was found to be safe and showed signs of efficacy in patients with previously treated RAS-mutant metastatic pancreatic cancer, according to a Phase I/II ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results